Amarin Corp Plc (AMRN)

[HDGabor]

m-

The Patents-In-Suit (Asserted Claims)

6 patents … 10 Claims are the topic.

U.S. Patent No. 8,293,728 (“the ‘728 Patent”), Claim 1 & Claim 16
U.S. Patent No. 8,318,715 (“the ‘715 Patent”), Claim 14
U.S. Patent No. 8,357,677 (“the ‘677 Patent”), Claim 1 & Claim 8
U.S. Patent No. 8,367,652 (“the ‘652 Patent”), Claim 1
U.S. Patent No. 8,431,560 (“the ‘560 Patent”), Claim 4 & Claim 17
U.S. Patent No. 8,518,929 (“the ‘929 Patent”), Claim 1 & Claim 5

Yes, the '728 contains a reference to Kurabayashi … but is not about ApoB reduction.
ApoB is part of the U.S. Patent No. 8,318,715 (“the ‘715 Patent”) Claim 14, U.S. Patent No. 8,357,677 (“the ‘677 Patent”) Claim 8 and U.S. Patent No. 8,518,929 (“the ‘929 Patent”) Claim 5.

'728 is a is a continuation of co-pending U.S. application Ser. No. 12/702,889 ('727 patent). The co-pending U.S. application Ser. No. 12/702,889 ('727 patent) was approved as (see Doc 262)

Applicant was able to overcome the above 103 obviousness rejection by showing: … The prior art is either silent or teaches that there is no statistically significant change in Apo-B levels when patients with TG levels less than 150 mg/dl or between 150-499 mg/dl are treated with either 96% pure ethyl-EPA or a mixture of ethyl-EPA and DHA

Kurabayashi teaches differently:_ ss changes in Apo-B exist.

Best,
G